MHRA aids new approach to create malaria vaccine

The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) and the University of Oxford’s Jenner Institute collaborated to develop a new method of creating malaria vaccines, the agency said Tuesday.
This fourth case study will help create a viral vector, which researchers use to carry genetic material that will prevent or treat an individual disease.

Swedish study uncovers new malaria-fighting bacteria

A new family of bacteria that are common in malaria-carrying mosquitoes may now be able to fight malaria.
Scientists and researchers at Swedish University of Agricultural Sciences (SLU) and Uppsala University in Sweden, Justus-Liebig-Universität Giessen in Germany, and the Veterinärmedizinische Universität in Austria recently discovered the connection,
Their findings were published in a recent edition of International Journal of Systematic and Evolutionary Microbiology.

New malaria drug unleashes an immune system assault on infected cells

Howard Hughes Medical Institute investigator Joseph DeRisi is working on a new malaria treatment that makes infected red blood cells an inviting target for the human immune system. And the team behind the effort is ramping up a human safety study in healthy volunteers as the first step in the clinical journey to prove its effectiveness.

University of Buffalo Develops new transport System for DNA Vaccines for HIV, Malaria, HPV, and Other Major Illnesses

Its performance isn’t measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, influenza and other maladies.
Described recently in the Proceedings of the National Academy of Sciences, the technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses.

Novartis and Malaria No More help fulfill malaria treatment goal in Zambia by raising funds for three million treatments through Power of One

Novartis announced today that, through Power of One, enough funds have been raised to deliver three million antimalarial treatments for children in Zambia. Launched in September 2013, Malaria No More’s Power of One campaign is supported by Novartis as the exclusive treatment sponsor.

Genocea finds new malaria biomarker

Genocea Biosciences, Inc., announced on Wednesday that it has discovered a series of antigens that could be a biomarker of malaria.
Genocea develops T-cell-directed vaccines and immunotherapies. It recently presented its findings at the 63rd annual meeting of the American Society of Tropical Medicine and Hygiene in New Orleans. Its proprietary ATLAS antigen discovery medium revealed that malaria can leave a lasting dent on the immune system.

17th International Congress on Infectious Diseases

Organized and hosted by the International Society for Infectious Diseases (ISID)

From the ISID website


A significant step in understanding the binding of the malaria parasite to blood cells enabled by the ExpreS 2 technology platform

Biotech company ExpreS2ion® Biotechnologies announced the publication of the article: ‘Structure of malariainvasion protein RH5 with erythrocyte basigin and blocking antibodies’ in the high impact scientific journal Nature, with teams at the University of Oxford.
The scientists have been working together since the University of Oxford took a license to ExpreS2ions’ Drosophila Schneider-2 cell-based protein production technology platform – ExpreS2.

Sanofi, PATH begin shipments of new malaria treatment

Sanofi and PATH announced on Tuesday that the first large-scale shipments of an antimalarial treatment using a semisynthetic artemisinin derivative were shipped to malaria-endemic countries in Africa.
The ArteSunate AmodiaQuine Winthrop treatments are non-seasonal and have the potential of widening access of malaria drugs to millions of people by complementing botanically-derived supplies.